Earnings Tell The Story For Neurocrine Biosciences, Inc. (NASDAQ:NBIX) As Its Stock Soars 27%
May 11
Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 13, 2025
DataAggregated Company Financials
Companies564
- 7D-2.6%
- 3M-7.2%
- 1Y-12.1%
- YTD-6.2%
Over the last 7 days, the Biotech industry has dropped 8.7%, driven by declines in AbbVie and Vertex Pharmaceuticals of 5.9% and 15%, respectively. In contrast, Halozyme Therapeutics has gained 8.7%. The industry has fallen 15% in the last year. As for the next few years, earnings are expected to grow by 24% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 13 May 2025 | US$865.3b | US$155.1b | -US$24,600,766,978.05 | 16.9x | -35.2x | 5.6x |
| Thu, 10 Apr 2025 | US$704.8b | US$118.6b | -US$36,908,648,987.19 | 21.5x | -19.1x | 5.9x |
| Sat, 08 Mar 2025 | US$845.1b | US$119.0b | -US$37,271,574,129.99 | 17.2x | -22.7x | 7.1x |
| Mon, 03 Feb 2025 | US$1.0t | US$149.5b | -US$26,306,804,829.57 | 17.2x | -38.1x | 6.7x |
| Wed, 01 Jan 2025 | US$960.8b | US$149.6b | -US$26,363,797,961.52 | 16.9x | -36.4x | 6.4x |
| Fri, 29 Nov 2024 | US$1.0t | US$150.0b | -US$26,596,552,206.01 | 16.6x | -39.1x | 6.9x |
| Sun, 27 Oct 2024 | US$888.6b | US$113.1b | -US$36,033,068,263.01 | 20.6x | -24.7x | 7.9x |
| Tue, 24 Sep 2024 | US$920.0b | US$113.2b | -US$35,983,947,157.41 | 21.9x | -25.6x | 8.1x |
| Thu, 22 Aug 2024 | US$903.8b | US$113.2b | -US$35,868,195,932.56 | 23.3x | -25.2x | 8x |
| Sat, 20 Jul 2024 | US$1.2t | US$164.5b | -US$28,047,850,966.89 | 29x | -42.5x | 7.3x |
| Mon, 17 Jun 2024 | US$1.2t | US$164.4b | -US$27,941,797,208.37 | 27.3x | -41.4x | 7x |
| Wed, 15 May 2024 | US$1.1t | US$164.6b | -US$27,141,970,719.54 | 27.5x | -41.5x | 6.8x |
| Fri, 12 Apr 2024 | US$1.1t | US$164.3b | -US$23,380,537,394.48 | 21x | -48x | 6.8x |
| Sun, 10 Mar 2024 | US$1.2t | US$167.3b | -US$22,140,783,177.03 | 19x | -53.9x | 7.1x |
| Tue, 06 Feb 2024 | US$1.3t | US$196.1b | -US$18,610,955,456.92 | 17.5x | -70.8x | 6.7x |
| Thu, 04 Jan 2024 | US$1.4t | US$204.8b | -US$22,306,519,032.00 | 20.9x | -63.4x | 6.9x |
| Sat, 02 Dec 2023 | US$1.3t | US$204.7b | -US$22,044,035,456.00 | 19x | -56.7x | 6.1x |
| Mon, 30 Oct 2023 | US$1.2t | US$206.6b | -US$15,116,353,891.00 | 16.3x | -78x | 5.7x |
| Wed, 27 Sep 2023 | US$1.3t | US$207.4b | -US$12,903,835,924.00 | 17.2x | -98.3x | 6.1x |
| Fri, 25 Aug 2023 | US$1.3t | US$207.6b | -US$12,461,259,012.00 | 17.3x | -102.1x | 6.1x |
| Sun, 23 Jul 2023 | US$1.2t | US$186.6b | -US$16,026,393,300.00 | 12.8x | -72x | 6.2x |
| Tue, 20 Jun 2023 | US$1.2t | US$186.3b | -US$16,029,005,553.00 | 12.1x | -72.4x | 6.2x |
| Thu, 18 May 2023 | US$1.1t | US$186.1b | -US$15,822,861,311.00 | 13.3x | -72.4x | 6.2x |
| Sat, 15 Apr 2023 | US$1.2t | US$198.5b | -US$3,247,497,685.00 | 14.1x | -361.6x | 5.9x |
| Mon, 13 Mar 2023 | US$1.1t | US$199.3b | -US$4,753,099,202.00 | 14.9x | -230.1x | 5.5x |
| Wed, 08 Feb 2023 | US$1.2t | US$202.3b | US$1.4b | 16.5x | 806.8x | 5.8x |
| Fri, 06 Jan 2023 | US$1.2t | US$203.1b | US$1.5b | 14.4x | 751.8x | 5.7x |
| Sun, 04 Dec 2022 | US$1.2t | US$202.6b | US$1.4b | 15.1x | 842.2x | 5.8x |
| Tue, 01 Nov 2022 | US$1.1t | US$205.8b | US$7.3b | 14.2x | 148.4x | 5.3x |
| Thu, 29 Sep 2022 | US$1.1t | US$205.8b | US$5.6b | 15.1x | 187.7x | 5.1x |
| Sat, 27 Aug 2022 | US$1.0t | US$206.2b | US$7.3b | 15.2x | 143x | 5x |
| Mon, 25 Jul 2022 | US$1.1t | US$211.4b | US$11.3b | 15.8x | 94.4x | 5x |
| Wed, 22 Jun 2022 | US$979.8b | US$212.4b | US$11.0b | 15.1x | 88.7x | 4.6x |
| Fri, 20 May 2022 | US$997.1b | US$212.4b | US$10.8b | 14.9x | 92.2x | 4.7x |
Price to Earnings Ratio
92.2x
Current Industry PE
- Investors are pessimistic on the American Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 6.3x is higher than the industry's current PS ratio of 5.6x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 10.0% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 3.92% | |
| Healthcare | -1.13% | |
| Biotech | -2.58% | |
| Biotech | -2.58% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | US$120.43 | 9.7% +US$1.1b | -11.5% | PE39x | |
| GILD Gilead Sciences | US$103.82 | 1.0% +US$978.2m | 53.7% | PE21.7x | |
| HALO Halozyme Therapeutics | US$66.58 | 9.8% +US$715.5m | 52.7% | PE16.9x | |
| ALVO Alvotech | US$10.25 | 23.0% +US$579.5m | -22.9% | PE32x | |
| UTHR United Therapeutics | US$310.80 | 4.1% +US$545.8m | 17.6% | PE11.6x |
